KRAS and cancer: To substantiate TET gene downregulation in CIMP-CCs, we performed immunohistochemical (IHC) analyses; BRAFV600E-mutated (by inference CIMP) CCs showed a significantly lower proportion of TET1 expressing cells (median 0%) than KRASG12/13-mutated (median 30%), or BRAF and KRAS wild-type cancers (BRAFWT/KRASWT; median 60%; Fig. 2b).